Literature DB >> 8709642

Supression of telomerase activity in HL60 cells after treatment with differentiating agents.

D Xu1, A Gruber, C Peterson, P Pisa.   

Abstract

The human promyelocytic leukemic HL60 cells are immortal and as such express high levels of telomerase activity. All-trans retinoic acid (ATRA) and 1 alpha, 25 dihydroxyvitamin D3 (VD3) induce differentiation of HL60 cells into CD11b+ mature granulocytes and monocytes, respectively. We studied telomerase activity after differentiation of HL60 cells. A marked inhibition of the enzyme activity was observed in the differentiated CD11b+ cells after 72-120 h treatment with either differentiating agent. In contrast, the VD3-treated CD11b- HL60 cells, which failed to undergo differentiation and human erythroleukemic cell line K562, exposed to ATRA retained high levels of telomerase activity. This finding suggests, that telomerase activity is repressed as a differentiation-associated event in HL60 cells. Our results provide the first evidence that immortal leukemic cells, like normal human cells, have a telomerase repressing mechanism which can be activated by differentiation and thus lead to the suppression of telomerase activity. This in vitro model may be useful for studies of the mechanisms controlling telomerase activity and in the search for physiological telomerase modulators.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709642

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

Review 1.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

Review 2.  Complex regulation of telomerase activity: implications for cancer therapy.

Authors:  K S Elenitoba-Johnson
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

3.  The expression of telomeric proteins and their probable regulation of telomerase during the differentiation of all-trans-retinoic acid-responsive and -resistant acute promyelocytic leukemia cells.

Authors:  Jie Sun; He Huang; Yuanyuan Zhu; Jianping Lan; Jingyuan Li; Xiaoyu Lai; Jian Yu
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

Review 4.  Telomerase activity, cell proliferation, and cancer.

Authors:  C W Greider
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

Review 5.  Genetic and epigenetic trends in telomere research: a novel way in immunoepigenetics.

Authors:  Dora Melicher; Edit I Buzas; Andras Falus
Journal:  Cell Mol Life Sci       Date:  2015-07-20       Impact factor: 9.261

6.  Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation.

Authors:  F Pendino; M Flexor; F Delhommeau; D Buet; M Lanotte; E Segal-Bendirdjian
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

7.  Expression of telomerase activity and oxidative stress in human hepatocellular carcinoma with cirrhosis.

Authors:  Dao-Yong Liu; Zhi-Hai Peng; Guo-Qiang Qiu; Chong-Zhi Zhou
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

8.  Promoter G-quadruplex sequences are targets for base oxidation and strand cleavage during hypoxia-induced transcription.

Authors:  David W Clark; Tzu Phang; Michael G Edwards; Mark W Geraci; Mark N Gillespie
Journal:  Free Radic Biol Med       Date:  2012-05-01       Impact factor: 7.376

9.  Design of a ribozyme targeting human telomerase reverse transcriptase and cloning of it's gene.

Authors:  Zhi-Ming Hao; Jin-Yan Luo; Jin Cheng; Quan-Yin Wang; Guang-Xiao Yang
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

10.  Lysine-specific demethylase 1 (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.

Authors:  Qingjun Zhu; Cheng Liu; Zheng Ge; Xiaolei Fang; Xi Zhang; Klas Strååt; Magnus Björkholm; Dawei Xu
Journal:  PLoS One       Date:  2008-01-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.